首页>Cancer Chemotherapy and Pharmacology>Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
Characterizing the disposition, metabolism, and excretion of an orally active pan-deacetylase inhibitor, panobinostat, via trace radiolabeled 14C material in advanced cancer patients
作者单位:Novartis Oncology, Florham Park, NJ, United States[1]Edinburgh Cancer Centre, Western General Hospital, Crewe Road South, Edinburgh EH4 2XU, United[2]Charles River, Tranent, Edinburgh, United Kingdom[3]Novartis Drug Metabolism and Pharmacokinetics, East Hanover, NJ, United States[4]